Does David Sinclair Still Take Metformin? Surprising Updates on His Anti-Aging Routine

If you follow longevity research you’ve probably heard David Sinclair’s name. As a leading scientist in aging and a bestselling author he’s often in the spotlight for his personal health choices—especially his use of supplements like metformin.

You might be wondering if Sinclair still takes metformin given the ongoing debates about its benefits and risks. With new studies and shifting opinions in the health community it’s natural to want the latest updates on what experts like Sinclair are actually doing.

Who Is David Sinclair?

David Sinclair is a Harvard Medical School professor and geneticist specializing in aging research. Sinclair co-directs the Paul F. Glenn Center for Biology of Aging Research at Harvard and holds co-inventor status on more than 50 patents in aging therapeutics, according to Harvard profiles. His best-selling book “Lifespan: Why We Age – and Why We Don’t Have To” and frequent podcast appearances have made longevity science widely accessible. Media platforms such as The Joe Rogan Experience, Lex Fridman Podcast, and his own Lifespan Podcast feature his commentary on geroscience and anti-aging interventions like metformin, resveratrol, and NAD+ precursors. You’ll also find Sinclair cited in high-impact research articles across Nature, Cell, and Science.

David Sinclair’s Approach to Longevity

You find David Sinclair’s approach to longevity centers on interventions that target aging at the cellular level. He highlights calorie restriction and intermittent fasting as essential strategies based on studies in yeast, mice, and humans—examples include the CALERIE trial and animal lifespan investigations. Sinclair also prioritizes compounds like metformin, resveratrol, and NAD+ precursors, citing their links to AMPK activation, sirtuin modulation, and cellular energy maintenance.

You see Sinclair frequently discuss lifestyle habits like regular exercise and plant-based diets, connecting them to improved mitochondrial function and reduced inflammation. He embraces ongoing self-experimentation, adjusting his supplement and medication routine as evidence shifts. For instance, Sinclair’s evolving stance on metformin aligns with new findings, especially those related to its effects on exercise adaptations in older adults.

You benefit from his transparent updates on public podcasts and interviews, where Sinclair shares insights and cautions about emerging research. He often notes collaboration with other experts—such as Dr. Nir Barzilai—when discussing the broader context of anti-aging drugs and clinical trials.

Want to stay up to date with the latest longevity podcasts weekly? Subscribe to The Longevity Digest here.

The History of David Sinclair Taking Metformin

David Sinclair started discussing metformin's potential impact on human aging more than a decade ago. Your understanding of his choices reveals the progression of views on metformin in the longevity field.

Early Advocacy of Metformin

Sinclair began publicly describing metformin as a promising intervention for healthy aging during the early 2010s. He cited observational studies—such as the UKPDS and cohort meta-analyses—that linked metformin use in type 2 diabetics with lower all-cause mortality. He identified metformin’s activation of AMP-activated protein kinase (AMPK) as a key mechanism, drawing connections with caloric restriction, which showed lifespan extension in model organisms like mice and C. elegans.

In podcast appearances and publications, Sinclair included metformin on his list of daily interventions. For example, he detailed his regimen on episodes of The Tim Ferriss Show and in his 2019 book “Lifespan.” Sinclair documented taking 500mg metformin either with or after meals, without diabetes, to possibly reduce cancer and cardiovascular risk based on literature from studies such as Bannister et al., 2014 (Lancet Diabetes Endocrinol.).

Public Statements and Interviews

Sinclair updated his stance through social media, interviews, and podcasts, explaining refinements to his routine based on new research. In 2021 and 2022, he addressed exercise-induced mitochondrial biogenesis in older adults, mentioning new studies—like Konopka et al., 2019 (Aging Cell)—suggesting that metformin may blunt exercise benefits. Sinclair confirmed pausing metformin on days when exercising intensely, especially after age 45, reflecting his personalized risk-benefit analysis.

You find his most recent statements, including conversations with Dr. Peter Attia and Dr. Nir Barzilai, where Sinclair emphasizes metformin’s possible cancer and cardiovascular protective effects but also its need for periodic reevaluation. Sinclair combines anecdotal experience with peer-reviewed evidence in these updates, supporting ongoing debate in the longevity field.

Want to stay up to date with the latest longevity podcasts weekly? Subscribe to The Longevity Digest here.

Recent Updates: Does David Sinclair Still Take Metformin?

David Sinclair often updates his supplement routine to reflect new research and expert discussions. His current approach to metformin remains a topic of interest as he shares developments across interviews and podcasts.

Changes in His Supplement Regimen

Sinclair has adjusted his use of metformin based on the latest evidence and ongoing debates in longevity research. Initially, he took 500mg daily, citing supporting data in diabetic longevity and cancer risk reduction. In interviews after 2020, he describes no longer taking metformin on days with intensive exercise, referencing findings that metformin may interfere with muscle adaptation in older adults (Attia, 2021). By 2023, Sinclair mentioned periods of discontinuation, preferring to pause metformin when focusing on improving exercise performance or recovery. These updates appear regularly in his conversations with experts on longevity podcasts.

Reasons for Possible Discontinuation

Concerns about metformin’s impact on strength training recovery prompted Sinclair’s adjustments. Clinical evidence from studies such as Konopka et al., 2019, in Cell Metabolism, and Malin & Gerber, 2021, in JCI Insight, describes reduced muscle gains when metformin is combined with resistance exercise in older adults. Sinclair cites these reports as reasons to abandon daily use in favor of a more individualized approach, especially during intense training blocks. He continues to evaluate new data, remaining open to restarting or pausing use as rigorous trial results become available.

Want to stay up to date with the latest longevity podcasts weekly? Subscribe to The Longevity Digest here.

Scientific Debate Around Metformin and Longevity

Expert consensus remains divided about metformin’s role in promoting longevity. Metformin, a first-line type 2 diabetes drug, appears in clinical trials and observational studies as both promising and controversial for healthy aging interventions.

Benefits of Metformin

Evidence links metformin to extended lifespan in type 2 diabetics compared to non-diabetics, based on studies like UKPDS and the Diabetes Prevention Program Research Group. Trials such as TAME (Targeting Aging with Metformin) explore its effects on age-related diseases including cancer, cardiovascular disease, and frailty. Researchers highlight anti-inflammatory, mitochondrial, and mTOR pathway modulation properties as mechanisms that may slow cellular aging. Notable researchers including Dr. Nir Barzilai and Dr. David Sinclair cite lower rates of mortality, cancer, and cognitive decline in metformin users, attributing these findings to retrospective epidemiological data.

Potential Risks and Criticisms

Skepticism persists about metformin’s safety and efficacy for non-diabetic, healthy adults. Concerns center on data indicating that metformin may blunt muscle strength and adaptation in older adults performing resistance training, shown in clinical trials by Short et al. and Konopka et al. Some studies suggest negative interactions with exercise interfere with mitochondrial improvements and muscle growth. Experts caution against widespread off-label use due to gastrointestinal side effects, vitamin B12 deficiency risk, and uncertain long-term outcomes in non-diabetics. Critics argue that metformin’s risk-benefit ratio remains unclear until results from large randomized controlled trials like TAME are published.

Want to stay up to date with the latest longevity podcasts weekly? Subscribe to The Longevity Digest here.

What We Can Learn from David Sinclair’s Choices

Observing David Sinclair's nuanced relationship with metformin gives you actionable insights into personalizing longevity strategies. Sinclair adapts his regimen based on the latest peer-reviewed research and shifting clinical guidelines. His willingness to change supplement routines, such as pausing metformin on intense exercise days or discontinuing it during periods prioritizing muscle adaptation, demonstrates a flexible evidence-based approach.

Adopting a similar principle, you can track reputable clinical data and adapt health interventions to match your goals and emerging science. Sinclair shows that interventions like metformin, NAD+ precursors, and intermittent fasting may not have universal effects and often require customization. When reviewing Sinclair’s evolving decisions, you see that expert consensus in geroscience remains dynamic and subject to revision.

If you perform regular endurance or strength training, Sinclair’s practice of timing or pulsing metformin may apply, since randomized trials indicate blunted muscle gains in older adults combining the drug with resistance exercise. Consulting clinical trial results such as those published in Cell Metabolism and Annals of Internal Medicine can clarify these effects for your demographic.

Monitoring public updates from credible researchers like Sinclair allows you to adjust strategies rather than following static routines. Individualizing supplement plans based on reliable evidence and transparent expert feedback enables you to make more informed longevity decisions, mirroring Sinclair’s risk-benefit assessment process.

Want to stay up to date with the latest longevity podcasts weekly? Subscribe to The Longevity Digest here.

Conclusion

David Sinclair’s evolving approach to metformin highlights the importance of staying flexible and informed as new research emerges. If you’re considering supplements or medications for longevity, it’s wise to keep an open mind and adjust your routine as evidence develops.

By following credible experts and prioritizing your personal health goals, you can make choices that fit your unique needs. Staying engaged with the latest science will help you navigate the changing landscape of longevity strategies with confidence.

Frequently Asked Questions

Who is David Sinclair and what is he known for?

David Sinclair is a Harvard Medical School professor, geneticist, and co-director of the Paul F. Glenn Center for Biology of Aging Research. He is best known for his research on aging, longevity, and interventions like metformin and NAD+ precursors. He authored the best-selling book "Lifespan: Why We Age – and Why We Don’t Have To."

Does David Sinclair still take metformin?

David Sinclair has modified his use of metformin. He no longer takes it on days when he performs intense exercise due to evidence that it may blunt muscle adaptation. Sinclair continually reviews new research and sometimes pauses or adjusts his metformin routine based on the latest scientific findings.

Why does Sinclair adjust his metformin routine around exercise?

Research suggests that metformin may interfere with muscle strength and gains in older adults during resistance training. To optimize exercise benefits, Sinclair avoids taking metformin on days with intensive workouts and adapts his supplement routine as needed.

Is metformin recommended for healthy individuals seeking longevity?

Metformin’s benefits for non-diabetic, healthy individuals remain debated. While some evidence links it to lower mortality, especially in diabetics, concerns exist about side effects and reduced muscle gains during exercise. Its off-label use should be considered cautiously and always discussed with a healthcare provider.

What other anti-aging interventions does Sinclair support?

In addition to metformin, Sinclair promotes calorie restriction, intermittent fasting, regular exercise, and a plant-based diet. He also takes supplements like resveratrol and NAD+ precursors, focusing on interventions that target aging at the cellular level.

What is the TAME Trial and why is it important?

The TAME (Targeting Aging with Metformin) trial is a large, randomized controlled study investigating whether metformin can extend lifespan and reduce age-related diseases in non-diabetic older adults. Its results are highly anticipated and will help clarify metformin’s role in longevity science.

How does Sinclair share updates about his longevity regimen?

Sinclair regularly discusses his health practices, new research, and supplement routine through public podcasts, interviews, and collaborations with other experts. He emphasizes staying updated with evidence-based information and adapting strategies as new findings emerge.

What lessons can readers take from Sinclair’s approach to longevity?

Sinclair’s adaptable, evidence-driven approach encourages individuals to personalize their health and supplement routines based on reputable research. Regularly reevaluating interventions and consulting healthcare professionals can help tailor longevity strategies to individual needs and goals.